Who owns organon pharmaceuticals

We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals — including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases — as we aspire to be the premier research-intensive biopharmaceutical company in the world.

For more information, visit www. Private Securities Litigation Reform Act of If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date. By continuing, you will be directed to a site intended only for residents of the United States and Canada.

Sign up for email alerts. Related links. Company Statements Read our latest company statements. Keep up to date on all things Organon by checking out our latest news. Private Securities Litigation Reform Act of By their nature, forward-looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. Although these statements are based on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and you should not place undue reliance on them.

Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Skip to content.

Here for her health. At the time of the acquisition, Organon Bioscienes comprised primarily of Organon, a human health business, and Intervet, an animal health business. It also included Nobilon, a human vaccine development unit, and Diosynth, a third-party manufacturing unit of Organon, which was subsequently sold to Fujifilm in to form Fujifilm Diosynth Biotechnologies. Overall, Organon has more than 60 products, with the largest number and revenue from its established brands business. This portfolio includes brands beyond their patent loss in most markets, with only modest remaining loss-of-exclusivity exposure beyond , according to information from Merck as reported in May Under the agreement, Organon will gain exclusive worldwide rights to develop and commercialize ebopiprant.

In June June , Organon completed the acquisition of Alydia Health, a commercial-stage medical-device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage or abnormal postpartum uterine bleeding.